CD274 and non-small cell lung carcinoma: In the first-line setting for advanced NSCLC without actionable genomic alterations, several large phase III trials have demonstrated that combining ICIs with chemotherapy significantly improves overall survival (OS) compared to chemotherapy alone, regardless of PD-L1 expression levels.